CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus

Genetic variations in the ITGAM gene (encoding CD11b) strongly associate with risk for systemic lupus erythematosus (SLE). Here we have shown that 3 nonsynonymous ITGAM variants that produce defective CD11b associate with elevated levels of type I interferon (IFN-I) in lupus, suggesting a direct lin...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of clinical investigation Vol. 127; no. 4; pp. 1271 - 1283
Main Authors Faridi, Mohd Hafeez, Khan, Samia Q, Zhao, Wenpu, Lee, Ha Won, Altintas, Mehmet M, Zhang, Kun, Kumar, Vinay, Armstrong, Andrew R, Carmona-Rivera, Carmelo, Dorschner, Jessica M, Schnaith, Abigail M, Li, Xiaobo, Ghodke-Puranik, Yogita, Moore, Erica, Purmalek, Monica, Irizarry-Caro, Jorge, Zhang, Tingting, Day, Rachael, Stoub, Darren, Hoffmann, Victoria, Khaliqdina, Shehryar Jehangir, Bhargava, Prachal, Santander, Ana M, Torroella-Kouri, Marta, Issac, Biju, Cimbaluk, David J, Zloza, Andrew, Prabhakar, Rajeev, Deep, Shashank, Jolly, Meenakshi, Koh, Kwi Hye, Reichner, Jonathan S, Bradshaw, Elizabeth M, Chen, JianFeng, Moita, Luis F, Yuen, Peter S, Li Tsai, Wanxia, Singh, Bhupinder, Reiser, Jochen, Nath, Swapan K, Niewold, Timothy B, Vazquez-Padron, Roberto I, Kaplan, Mariana J, Gupta, Vineet
Format Journal Article
LanguageEnglish
Published United States American Society for Clinical Investigation 01.04.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Genetic variations in the ITGAM gene (encoding CD11b) strongly associate with risk for systemic lupus erythematosus (SLE). Here we have shown that 3 nonsynonymous ITGAM variants that produce defective CD11b associate with elevated levels of type I interferon (IFN-I) in lupus, suggesting a direct link between reduced CD11b activity and the chronically increased inflammatory status in patients. Treatment with the small-molecule CD11b agonist LA1 led to partial integrin activation, reduced IFN-I responses in WT but not CD11b-deficient mice, and protected lupus-prone MRL/Lpr mice from end-organ injury. CD11b activation reduced TLR-dependent proinflammatory signaling in leukocytes and suppressed IFN-I signaling via an AKT/FOXO3/IFN regulatory factor 3/7 pathway. TLR-stimulated macrophages from CD11B SNP carriers showed increased basal expression of IFN regulatory factor 7 (IRF7) and IFN-β, as well as increased nuclear exclusion of FOXO3, which was suppressed by LA1-dependent activation of CD11b. This suggests that pharmacologic activation of CD11b could be a potential mechanism for developing SLE therapeutics.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Authorship note: M.H. Faridi, S.Q. Khan, W. Zhao, H.W. Lee, and M.M. Altintas contributed equally to this work.
ISSN:0021-9738
1558-8238
DOI:10.1172/JCI88442